BetterLife Pharma

BetterLife Pharma

Private Company
Public Company
Subsidiary of
Clinic Operator


BetterLife Pharma is a life sciences company creating and clinically validating an evolving intellectual property portfolio of novel molecules and drug delivery mechanisms for clinical trials and commercialization.

BetterLife's drug candidates include three compelling and differentiated assets.

Second Generation (non-hallucinogenic)
TD-0148A: 2-bromo-LSD (oral)

▪ Indication: Major depressive disorder (MDD)

▪ IND filing projected Q1 2022

▪ IP: Two manufacturing patents that eliminate controlled substance regulatory controls (issued); Method of use (pending)
TD-010: DHH-B (oral)

▪ Indication: Benzodiazepine dependency

▪ IND filing projected Q1 2022

▪ IP: Method of use (pending)
AP-003: Inhaled interferon alpha-2b (IFN⍺2b)

▪ Indication: Early stage Covid-19 infection

▪ IND filing projected Dec 2021

▪ IP: Composition and formulation (pending)


Ahmad Doroudian, PhD Founder, CEO

20+ years experience in finance, M&A,

Founder of Merus Labs (NASDAQ: MSLI), sold for $300M+

Scott Rudge, PhD, Head of CMC

- Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since

- Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin

- PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles

Abdi Ghaffari, PhD, Head of Preclinical Research

15+ years, Pre-Clinical R&D

Patrick Kroupa, Chief of Psychedelic Therapy Research

CTO of the Ibogaine Research Project

Founder of Clear Sky Recovery- ibogaine treatment clinic

Justin Kirkland, MSc, Head of Psychedelic Chemistry & Synthesis

20+ years in natural product chemistry, peptide synthesis and analytical chemistry